1900 Wealth Management’s Cellectar Biosciences CLRB Stock Holding History

1900 Wealth Management’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-600	Closed	-$35.1K	–	294
2023 Q2	$35.1K	Buy	600 +200	+50%	+$9.62K	﹤0.01%	237
2023 Q1	$20.5K	Hold	400	–	–	﹤0.01%	240
2022 Q4	$20.5K	Hold	400	–	–	﹤0.01%	234
2022 Q3	$40K	Buy	+400	New	+$57.5K	﹤0.01%	219
2022 Q2	–	Sell	-400	Closed	-$83K	–	225
2022 Q1	$83K	Buy	400 +200	+100%	+$35K	0.01%	237
2021 Q4	$40K	Hold	200	–	–	﹤0.01%	240
2021 Q3	$56K	Hold	200	–	–	0.01%	214
2021 Q2	$71K	Buy	+200	New	+$86.7K	0.01%	213

Other funds holding CLRB

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

1900 Wealth Management's CLRB Position: Q3 2023 in Review

1900 Wealth Management sold out of Cellectar Biosciences (CLRB) in Q3 2023, closing a stake of 600 shares — an estimated $35.1K sold.

1900 Wealth Management first reported a position in CLRB in Q2 2021 and held it in 8 quarters. The position peaked at $83K in Q1 2022. 19 funds tracked by Wall St. Rank hold CLRB as of Q3 2023.

1900 Wealth Management reported no remaining Cellectar Biosciences position as of Q3 2023 after selling out during the quarter.
1900 Wealth Management sold 600 Cellectar Biosciences shares in Q3 2023, an estimated $35.1K.
1900 Wealth Management first reported a position in Cellectar Biosciences in Q2 2021 and held it in 8 quarters.
1900 Wealth Management's Cellectar Biosciences position peaked at $83K in Q1 2022.
19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2023.

Based on 1900 Wealth Management's 13F filing for Q3 2023, filed 17 Oct 2023.